On January 19, 2024, MindRank and Henlius (2696.HK) announced a strategic collaboration to jointly develop two innovative healthcare solutions. One is an AI-driven antibody-drug conjugates (ADCs) drug discovery platform, which will expedite the research and development (R&D) of next-generation ADCs with better clinical efficacy. The other solution is an AI-driven anti-aging therapy platform, which will be developed by leveraging MindRank's biomedical AI large language model (LLM). This collaboration is expected to accelerate the advancement of these two AI-driven healthcare solutions.